摘要
肾细胞癌是癌症中有不同组织学亚型的异质群体。大多数成人肾肿瘤是透明细胞肾细胞癌,其特点是VHL基因的改变。最新肾癌基因特征的研究进展表明了透明细胞肾细胞癌(ccRCC) 遗传异质性和在染色体3 p上它至少存在3个额外ccRCC肿瘤抑制基因。因失活VHL肾癌细胞产生HIF-responsive VEGF生长因子。PI3K--mTORC1信号轴也代表着一个治疗靶点。新的系统性疗法,包括单克隆抗体、酪氨酸激酶抑制剂、mTOR旨在将抑制血管生成和血管内皮的生长因子作为靶点[1]。VEGF抑制剂被批准用于治疗各种ccRCC和我们将讨论在治疗转移性ccRCC最新展。其他基因改变在遗传性癌症综合征已确定,例如FLCN、TSC1、TSC2、TFE3、TFEB、MITF、FH、SDHB、SDHD、MET和PTEN。我们综述了他们在肾肿瘤的癌变、预后、个体化治疗中起到的作用。通过综述形态学和肾癌分子遗传学之间的关联特性,为肾癌靶点治疗提供基础。
关键词: 肾癌靶向治疗,个体化医学
Current Drug Targets
Title:Oncotargets in Different Renal Cancer Subtypes
Volume: 16 Issue: 2
Author(s): Holger Moch, Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng and Axel Mischo
Affiliation:
关键词: 肾癌靶向治疗,个体化医学
摘要: Renal cell cancer is a heterogeneous group of cancers with different histologic subtypes. The majority of renal tumors in adults are clear cell renal cell carcinomas, which are characterized by von Hippel- Lindau (VHL) gene alterations. Recent advances in defining the genetic landscape of renal cancer has shown the genetic heterogeneity of clear cell renal cell carcinomas (ccRCC) and the presence of at least 3 additional ccRCC tumor suppressor genes on chromosome 3p. Due to inactivation of VHL, renal cancer cells produce the HIF-responsive growth factor VEGF. The PI3K--mTORC1 signaling axis also represents a target for therapy. The new systemic therapies, including tyrosine kinase inhibitors, monoclonal antibodies, and mTOR inhibitors, aim to suppress angiogenesis with vascular endothelial growth factor as a target [1]. Various VEGF-inhibitors are approved for the treatment of ccRCC and we discuss recent advancements in the treatment of metastatic ccRCC. Other gene alterations have been identified in hereditary cancer syndromes, e.g. FLCN, TSC1, TSC2, TFE3, TFEB, MITF, FH, SDHB, SDHD, MET, and PTEN and we review their role in renal tumor carcinogenesis, prognosis, and targeted therapy. By reviewing the associations between morphologic features and molecular genetics of renal cancer we provide insight into the basis for targeted renal cancer therapy.
Export Options
About this article
Cite this article as:
Holger Moch, Rodolfo Montironi, Antonio Lopez-Beltran, Liang Cheng and Axel Mischo , Oncotargets in Different Renal Cancer Subtypes, Current Drug Targets 2015; 16 (2) . https://dx.doi.org/10.2174/1389450116666150126110632
DOI https://dx.doi.org/10.2174/1389450116666150126110632 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry Heparin Oligosaccharides as Potential Therapeutic Agents in Senile Dementia
Current Pharmaceutical Design Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets The Opposite Effect of L-kynurenine and Ahr Inhibitor Ch223191 on Apoptotic Protein Expression in Pancreatic Carcinoma Cells (Panc-1)
Anti-Cancer Agents in Medicinal Chemistry Natural Killer Cells Preferentially Target Cancer Stem Cells; Role of Monocytes in Protection Against NK Cell Mediated Lysis of Cancer Stem Cells
Current Drug Delivery Calorie Restriction and Dietary Restriction Mimetics: A Strategy for Improving Healthy Aging and Longevity
Current Pharmaceutical Design Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Oxidative stress and myocarditis
Current Pharmaceutical Design Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry
Current Pharmaceutical Design Current Guidelines and Strategies in Management of Renal Vein Thrombosis
Current Pediatric Reviews Autoimmune Hepatitis
Current Pediatric Reviews Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine
Current Topics in Medicinal Chemistry Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Chemokines and Chemokine Receptors Blockers as New Drugs for the Treatment of Chronic Obstructive Pulmonary Disease
Current Medicinal Chemistry Gut-liver Axis and Microbiota in NAFLD: Insight Pathophysiology for Novel Therapeutic Target
Current Pharmaceutical Design Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs